EUVIMEDEUVIMED entdecken
Crossref

IL-23 and IL-33 Levels and Porphyromonas gingivalis in Peri-Implant Mucositis and Peri-Implantitis Patients: A Narrative Review

Dr Savita Sambashivaiah, Dr.Kranti Konuganti

International Journal of Drug Delivery Technology · 18.05.2026 · 16 (44s)

DOI: 10.25258/ijddt.16.44s.72 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 18.05.2026. Verfasst von Dr Savita Sambashivaiah und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peri-implant diseases are inflammatory diseases related to biofilm and jeopardize the success of implant therapy in the long term. Peri-implant mucositis is a reversible soft-tissue lesion among them, but peri-implantitis is progressive inflammatory destruction with supporting bone loss. There has been a growing interest in host-response biomarkers and keystone pathogens that could elucidate the progression of some lesions to be superficial and others to be progressive. The IL-23/IL17 axis has become a viable candidate to cause chronic inflammation and osteoclastogenic signaling, whereas IL-33 has been examined as an alarmin, which can enhance innate and adaptive immunity in peri-implant tissues. In parallel to these host mediators, Porphyromonas gingivalis has been implicated repeatedly in peri-implant dysbiosis due to its capacity to cause biofilm ecology disruption, immune clearance evasion and tissue-destructive inflammation potentiation. The article is a narrative review that summarizes the state of evidence on IL-23, IL-33 and P. gingivalis in peri-implant mucositis and peri-implantitis. It presents modern definitions and pathophysiology of peri-implant disease, summarizes clinical and laboratory data on the pattern of cytokine expression in peri-implant crevicular fluid, and critically reviews microbiologic studies assessing the role of P. gingivalis in diseased implant sites. The relevance of these markers in diagnosis, their weaknesses as single indicators, and how well existing therapeutic interventions can regulate these inflammatory pathways are also discussed. According to the available evidence, IL-23 is more regularly associated with the shift in peri-implant health to active inflammatory disease compared to IL-33, the literature on which is less extensive and more heterogeneous. P. gingivalis seems to be enriched in the peri-implant lesions, particularly peri-implantitis, but must be viewed as a component of a polymicrobial dysbiotic ecosystem and not an etiologic agent. Longitudinal and mechanistic research is required in the future to establish whether host-microbial profiling, together with host-microbial profiling, can enhance risk stratification, early diagnosis, and individualized treatment in peri-implant disease

Zitieren

APA

Sambashivaiah, D. S., & Konuganti, D. (2026). IL-23 and IL-33 Levels and Porphyromonas gingivalis in Peri-Implant Mucositis and Peri-Implantitis Patients: A Narrative Review. International Journal of Drug Delivery Technology, 16(44s). https://doi.org/10.25258/ijddt.16.44s.72

Vancouver

Sambashivaiah DS, Konuganti D. IL-23 and IL-33 Levels and Porphyromonas gingivalis in Peri-Implant Mucositis and Peri-Implantitis Patients: A Narrative Review. International Journal of Drug Delivery Technology. 2026;16(44s). doi:10.25258/ijddt.16.44s.72

BibTeX
@article{Sambashivaiah2026,
  author = {Sambashivaiah, Dr Savita and Konuganti, Dr.Kranti},
  title = {IL-23 and IL-33 Levels and Porphyromonas gingivalis in Peri-Implant Mucositis and Peri-Implantitis Patients: A Narrative Review},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {44s},
  doi = {10.25258/ijddt.16.44s.72}
}
Kostenlos starten →